{"id":9313,"date":"2023-10-10T16:33:50","date_gmt":"2023-10-10T14:33:50","guid":{"rendered":"https:\/\/www.icta.fr\/?p=9313"},"modified":"2026-06-08T15:12:47","modified_gmt":"2026-06-08T13:12:47","slug":"icta-resistance-antimicrobriens","status":"publish","type":"post","link":"https:\/\/www.icta.fr\/fr\/icta-resistance-antimicrobriens\/","title":{"rendered":"ICTA engag\u00e9 dans la r\u00e9sistance aux antimicrobiens via la plateforme S.O.L.V.E &#8211; AMR"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n<p><strong>Vous \u00eates acteur en R&amp;D et engag\u00e9 dans la lutte contre la r\u00e9sistance aux antimicrobiens (RAM) ?<\/strong><br \/><strong>Vous d\u00e9veloppez un programme d\u2019anti-infectieux\u00a0? <\/strong><\/p>\n<p><!-- \/wp:post-content --><!-- wp:paragraph {\"kioblocks\":[]} --><\/p>\n\n<!-- wp:paragraph {\"kioblocks\":[]} -->\n<p><\/p>\n<!-- \/wp:paragraph -->\n\n<p>Aujourd\u2019hui, 10 octobre 2023, lancement de la plateforme :<\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph {\"align\":\"center\",\"kioblocks\":[]} --><\/p>\n\n<p style=\"text-align: center;\"><strong>S.O.L.V.E &#8211; AMR<\/strong> <br \/><strong>(Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance)<\/strong><\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph {\"align\":\"center\",\"kioblocks\":[]} --><\/p>\n\n<p class=\"has-text-align-center\"><strong>4 prestataires reconnus en recherche clinique<\/strong><br \/><strong>BIOASTER, CYNBIOSE, ICTA et PHARMALEX<\/strong><!-- \/wp:paragraph --><!-- wp:paragraph {\"align\":\"left\",\"kioblocks\":[]} --><\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph {\"align\":\"center\",\"kioblocks\":[]} --><\/p>\n\n<!-- wp:paragraph {\"kioblocks\":[]} -->\n<p>associent leurs expertise et comp\u00e9tences pour vous proposer un accompagnement int\u00e9gr\u00e9 et innovant tout au long du cycle de d\u00e9veloppement de vos agents antimicrobiens.<br><br>De leur d\u00e9couverte \u00e0 leur enregistrement, en passant par leur d\u00e9veloppement pr\u00e9-clinique et clinique, <strong>S.O.L.V.E. &#8211; AMR<\/strong> propose des solutions adapt\u00e9es, des technologies innovantes pour acc\u00e9l\u00e9rer le passage de vos anti-infectieux de la R&amp;D clinique \u00e0 la commercialisation.<br><\/p>\n<!-- \/wp:paragraph -->\n\n<p>Pour plus d&#8217;informations, lire le communique de presse:<\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph {\"kioblocks\":[]} --><\/p>\n\n<!-- wp:paragraph {\"kioblocks\":[]} -->\n<p><a href=\"https:\/\/www.icta.fr\/wp-content\/uploads\/Press-release-Solve_AMR__Oct2023_Final-1.pdf\" class=\"ek-link\">https:\/\/www.icta.fr\/wp-content\/uploads\/Press-release-Solve_AMR__Oct2023_Final-1.pdf<\/a><\/p>\n<!-- \/wp:paragraph -->","protected":false},"excerpt":{"rendered":"<p>Vous \u00eates acteur en R&amp;D et engag\u00e9 dans la lutte contre la r\u00e9sistance aux antimicrobiens (RAM) ?Vous d\u00e9veloppez un programme d\u2019anti-infectieux\u00a0? Aujourd\u2019hui, 10 octobre 2023, lancement de la plateforme : S.O.L.V.E &#8211; AMR (Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance) 4 prestataires reconnus en recherche cliniqueBIOASTER, CYNBIOSE, ICTA et PHARMALEX associent leurs [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":9305,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","inline_featured_image":false,"_uag_custom_page_level_css":"","kk_blocks_editor_width":"","_kiokenblocks_attr":"","_kiokenblocks_dimensions":"","footnotes":""},"categories":[92],"tags":[],"class_list":["post-9313","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-non-classifiee"],"acf":[],"uagb_featured_image_src":{"full":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3.jpg",1280,720,false],"thumbnail":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3-128x88.jpg",128,88,true],"medium":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3-300x169.jpg",300,169,true],"medium_large":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3-768x432.jpg",768,432,true],"large":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3-1024x576.jpg",1024,576,true],"1536x1536":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3.jpg",1280,720,false],"2048x2048":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3.jpg",1280,720,false],"post-thumbnail":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3.jpg",1280,720,false],"wpm_taille_1":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3-364x257.jpg",364,257,true],"wpm_taille_slider":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3-240x145.jpg",240,145,true],"gform-image-choice-sm":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3.jpg",300,169,false],"gform-image-choice-md":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3.jpg",400,225,false],"gform-image-choice-lg":["https:\/\/www.icta.fr\/wp-content\/uploads\/2023-10_SOLVE_AMR-3.jpg",600,338,false]},"uagb_author_info":{"display_name":"Manon ROBERT","author_link":"https:\/\/www.icta.fr\/fr\/author\/mrobert-icta21\/"},"uagb_comment_info":0,"uagb_excerpt":"Vous \u00eates acteur en R&amp;D et engag\u00e9 dans la lutte contre la r\u00e9sistance aux antimicrobiens (RAM) ?Vous d\u00e9veloppez un programme d\u2019anti-infectieux\u00a0? Aujourd\u2019hui, 10 octobre 2023, lancement de la plateforme : S.O.L.V.E &#8211; AMR (Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance) 4 prestataires reconnus en recherche cliniqueBIOASTER, CYNBIOSE, ICTA et PHARMALEX associent leurs\u2026","_links":{"self":[{"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/posts\/9313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/comments?post=9313"}],"version-history":[{"count":2,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/posts\/9313\/revisions"}],"predecessor-version":[{"id":10997,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/posts\/9313\/revisions\/10997"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/media\/9305"}],"wp:attachment":[{"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/media?parent=9313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/categories?post=9313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.icta.fr\/fr\/wp-json\/wp\/v2\/tags?post=9313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}